Shares of PEIJIA-B (09996) extended their rally, climbing more than 5% during Monday's trading session. At the time of writing, the stock was up 3.14% at HK$5.58, with turnover reaching HK$1.25 million.

The company recently released its interim financial results, revealing several impressive core metrics. Total revenue for the first half of the year reached RMB 425 million, representing a 20.1% increase year-on-year. This growth, combined with meticulous management practices, has significantly boosted the company's earnings quality. Gross profit for the period amounted to RMB 290 million, up 17.1% from the prior year. Notably, both EBITDA and pre-tax profit turned positive, while the net loss narrowed sharply by 87.4% year-on-year to approximately RMB 8.99 million, putting the company on the cusp of profitability.

During the earnings conference call held on August 24, management raised its full-year TAVR implantation volume guidance for its valve business from the initial 5,000+ units projected earlier this year to a new range of 6,000 to 6,500 units. Within this, the regurgitation valve business is expected to achieve no fewer than 2,500 implantations for the full year, with revenue growth exceeding 30%, underscoring the management's strong confidence in the sustained expansion of this segment.